Page last updated: 2024-10-15

sauvagine

Description

sauvagine: isolated from skin of South American hylid frog, Phyllomedusa sauvagei; has hypotensive & antidiuretic effect; potent stimulating action on secretion of ACTH & corticosterone; inhibitory effect on secretion of PRL, GH, & TSH; consists of straight chain of 40 amino acid residues [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132335
MeSH IDM0085451

Synonyms (5)

Synonym
sauvagine
74434-59-6
sauvagin
AKOS024456704
DTXSID10225449

Research Excerpts

Overview

Sauvagine (SV) is a 40 amino acid peptide, isolated from the skin of the South American frog Phyllomedusa sauvagei. Sauvagine is structurally related to mammalian corticotropin releasing factor (CRF)

ExcerptReference
"Sauvagine is a 40 amino acid peptide, isolated from the skin of the South American frog, Phyllomedusa sauvagei, and structurally related to mammalian corticotropin releasing factor (CRF). "( Sauvagine: effects on thermoregulation in the rat.
Broccardo, M,
)
"Sauvagine (SV) is a forty amino acid peptide, isolated from the skin of the South American frog Phyllomedusa sauvagei and structurally related to fish Urotensin I (U1) and to mammalian corticotropin releasing factor (CRF). "( Effects of sauvagine, urotensin I and CRF on food intake in rats.
Negri, L; Noviello, L; Noviello, V, 1985
)

Treatment

Sauvagine treatment, which stimulates alpha-MSH release, lead to an elevation in the level of cyclic-AMP. The effect was potentiated by cholera toxin. Treatment with sauvagine increased phosphorylation of p42/p44, but not of p38.

ExcerptReference
"Sauvagine treatment, which stimulates alpha-MSH release, lead to an elevation in the level of cyclic-AMP, an effect which was potentiated by cholera toxin."( The CRF-related peptide sauvagine stimulates and the GABAB receptor agonist baclofen inhibits cyclic-AMP production in melanotrope cells of Xenopus laevis.
de Koning, HP; Jenks, BG; Leenders, HJ; Roubos, EW; van Zoest, ID, 1991
)
"Treatment with sauvagine increased phosphorylation of p42/p44, but not of p38 or stress-activated protein kinase (SAPK)/JUN N-terminal kinase (JNK) mitogen-activated protein (MAP) kinases correlating with increased p42/p44 MAP kinase activity."( Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3',5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase.
Hall, MD; Hughes, J; McNulty, S; Pinnock, RD; Rossant, CJ, 1999
)

Bioavailability

ExcerptReference
" Because xCRH-BP binds CRH-like peptides with high affinity the protein may regulated, the bioavailability of CRH in amphibia as it does in mammals."( Biochemical characterization and expression analysis of the Xenopus laevis corticotropin-releasing hormone binding protein.
Cortright, DN; Denver, RJ; Seasholtz, AF; Valverde, RA, 2001
)
" The data show that NBI 35965 is a novel water-soluble selective CRF1 antagonist with bioavailability to the brain upon peripheral administration and that CRF1 receptor signaling pathways are involved in water avoidance stress-induced hyperalgesia to colorectal distention and stimulation of colonic transit."( A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats.
Crowe, PD; Grigoriadis, DE; Maillot, C; Mayer, EA; McRoberts, JA; Million, M; Saunders, PR; Sullivan, S; Taché, Y; Zhou, H, 2003
)
"3 mg/kg and an oral bioavailability of 91."( 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism.
Ciccocioppo, R; Cippitelli, A; Cramer, J; Gehlert, DR; Hamdouchi, C; Heilig, M; Hembre, EJ; Hipskind, PA; Lê, AD; Lu, J; McKinzie, D; Morin, M; Song, M; Thorsell, A, 2007
)

Dosage Studied

ExcerptReference
" Dopamine and the GABAB receptor agonist baclofen both inhibited cyclic-AMP efflux and alpha-MSH release, with similar dynamics of inhibition and similar dose-response relationships."( Dynamics of cyclic-AMP efflux in relation to alpha-MSH secretion from melanotrope cells of Xenopus laevis.
de Koning, HP; Huchedé, B; Jenks, BG; Roubos, EW, 1992
)
" The CRF dose-response slopes for bovine CRF were somewhat steeper than those for ovine CRF or sauvagine in the in vitro system."( In vivo and in vitro comparisons of biological activities of bovine, ovine and rat CRF (corticotrophin-releasing factor).
Aizawa, T; Greer, MA; Maruta, S; Yasuda, N; Yasuda, Y, 1984
)
" Increasing the dosing period to 9 days reduced receptor binding by 78%."( Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS.
Lesher, T; Li, J; Livanov, V; Peng Ho, S; Zhang, W, 1998
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (171)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (28.65)18.7374
1990's45 (26.32)18.2507
2000's56 (32.75)29.6817
2010's19 (11.11)24.3611
2020's2 (1.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (3.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other173 (96.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]